| ²é¿´: 286 | »Ø¸´: 3 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
2110907077½ð³æ (³õÈëÎÄ̳)
|
[½»Á÷]
°ï°ï棬лл£¡
|
||
|
Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis. We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci,and enterococci. The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. U-100592 and U-100766 demonstrate potent in vitro activity against Mycobacterium tuberculosis. A novel and practical asymmetric synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones has been developed and is employed for the synthesis of U-100592 and U-100766. This involves the reaction of N-lithioarylcarbamates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate (R)-5-(hydroxymethyl)-2-oxazolidinones. |
» ²ÂÄãϲ»¶
Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
288Çóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó ²ÄÁÏÓ뻯¹¤
ÒѾÓÐ12È˻ظ´
085600£¬320·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
085600²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ27È˻ظ´
Çóµ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ²ÄÁÏÓ뻯¹¤×¨Ë¶£¬Ó¢¶þÊý¶þ342·Ö£¬ÇóÀÏʦÊÕÁô
ÒѾÓÐ19È˻ظ´
292Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
270»¯¹¤Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏ295
ÒѾÓÐ14È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
syh9288
¾èÖú¹ó±ö (ÖøÃûдÊÖ)
º£¾üÉϽ«
- ·ÒëEPI: 6
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 1605.6
- É¢½ð: 543
- ºì»¨: 1
- Ìû×Ó: 1070
- ÔÚÏß: 480Сʱ
- ³æºÅ: 735351
- ×¢²á: 2009-03-30
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
zap65535(½ð±Ò+6,VIP+0):²¹·¢ 12-25 01:14
zap65535(½ð±Ò+6,VIP+0):²¹·¢ 12-25 01:14
| ¶ÔÓÚÐí¶àÖÖ¿¹ÉúËØÀ´Ëµ£¬Ï¸¾úµÄ¿¹ÐÔÔöÇ¿ÒѳÉΪһ¸ö·Ç³£ÑÏÖØµÄÁÙ´²ÎÊÌâ¡£3-·¼»ù-2-¶ñßòÍé¶þͪÊǺϳɵÄÐÂÐÍ¿¹¾úÎËüÓÐ×ÅȫеÄ×÷ÓûúÖÆ£º½ÏÔçµØÒÖÖÆÏ¸¾úÌåÄÚµ°°×Öʵĺϳɡ£ÎÒÃÇÖÆ±¸ÁËÁ½Öֺϳɵõ½¡¢ÓÐҩЧµÄßòÍéͪÀ໯ºÏÎïU-100592ºÍU-100766,ĿǰÕý´¦ÓÚÁÙ´²¿ª·¢½×¶Î£¬ÓÃÓÚÖÎÁÆÒòÆÏÌÑÇò¾ú¾úÖê¡¢Á´Çò¾ú¾úÖêºÍ³¦Çò¾úÒýÆðµÄ¡¢ÑÏÖØµÄ¡¢¶Ô¶àÖÖÒ©Îï¶¼¾ßÓп¹ÐԵĸïÀ¼ÊÏÑôϸ¾úµÄ¸ÐȾ¡£ÎÞÂÛÊÇÔÚÌåÄÚ»¹ÊÇÔÚÌåÍ⣬U-100592 U-100766ÕâÁ½ÖÖ»¯ºÏÎï¶ÔÓÚµäÐ͵ľúÖêµÄ×÷Óùý³ÌÓëÍò¹ÅÃ¹ËØµÄºÜÏàËÆ¡£ÔÚÌåÍâʵÑéÖÐU-100592ºÍU-100766±íÏÖ³ö¶Ô·Î½áºË¸Ë¾úÓÐןÜÇ¿µÄЧ¹û¡£ÎÒÃÇ·¢ÏÖÁËÒ»ÖÖÐÂӱʵÓõÄ5S-ÒÒõ£°±°±¼×»ù-2-ßòÍé¶þͪ²»¶Ô³ÆºÏ³É·¨£¨5S-acetamidomethyl-2-oxazolidinones£©²¢Í¨¹ý´Ë·¨ºÏ³ÉÁËU-100592ºÍU-100766¡£ÕâÉæ¼°lithioarylcarbamatesÓë»·Ñõ±û»ù¶¡ËáÑεķ´Ó¦£¬Í¨¹ý´Ë·´Ó¦ÎÒÃÇÄܵõ½ºÜ¸ßµÄ²úÁ¿ºÍÖмäÌå(R)-2-ôǼ׻ù-2-¶ñßò¶þͪµÄ¸ß´¿¶È¶ÔÓ³Ìå¡£ |

2Â¥2009-12-18 22:18:24
zap65535(½ð±Ò+0,VIP+0):ÖÊÁ¿²»ºÏ¸ñ 12-25 01:14
| ¶ÔÐí¶à¿¹¾úѧÀ´½²£¬¿¹¾úÒ©Æ·µÄ¿ª·¢ÊǺÜÖØÒªµÄÁÙ´²ÎÊÌâ¡£The 3-aryl-2-oxazolidinones ÊÇÏà¶Ô½ÏÐÂÖÖÀàµÄºÏ³É¿¹¾ú¼Á£¬ËüµÄÐÂ×÷ÓûúÀí°üÀ¨ÔÚÔçÆÚ×èÖ¹²¡¾úµ°°×ÖÊµÄºÏ³É .ÎÒÃÇ×¼±¸ÁË2ÖÖÓÐЧµÄÈ˹¤ºÏ³É¼Áoxazolidinones, U-100592 ºÍ U-100766£¬ËüÃÇÊÇÏÖ½ñÁÙ´²·¢Õ¹ÉÏÕë¶ÔÓÉÆÏÌÑÌǾú¡¢Á´Çò¾úºÍ³¦Çò¾úÒýÆðµÄÑÏÖØµÄ¶àÖØÄÍÒ©ÐÔ¸ïÀ¼ÊÏ(Ⱦɫ)ÑôÐÔϸ¾ú¸ÐȾµÄÖÎÁÆÒ©Æ·¡£The in vitro and in vivo (po and iv) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. ÔÚ¶Ô¿¹µäÐ͵ļ²²¡ÀàÐÍÖУ¬U-100592 ºÍU-100766 ÔÚÊÔ¹ÜÖкÍÓлúÌåÄڵĻîÔ¾ÐÔºÍÍò¹ÅÃ¹ËØÏàËÆ |
3Â¥2009-12-18 23:24:39
15890734984
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2057.3
- É¢½ð: 101
- Ìû×Ó: 263
- ÔÚÏß: 60.4Сʱ
- ³æºÅ: 903027
- ×¢²á: 2009-11-14
- רҵ: Ó¦ÓÃÓлú»¯Ñ§
telomerase(½ð±Ò+0,VIP+0):»úÒëÇë˵Ã÷£¬·ñÔòÑϳͣ¡£¡£¡ 12-19 18:31
|
ÄÍÒ©µÄ·¢Õ¹ÒѳÉΪһ¸ö·Ç³£ÑÏÖØµÄÎÊÌâ,Ðí¶àÀ࿹ÉúËØ¡£Õâ¸ö3-aryl-2-oxazolidinonesÊǸöÐÂÉú°àµÄ¿¹¾úÒ©ÎïºÏ³É¡¢ÐÂÐ͵Ä×÷ÓûúÖÆÉæ¼°·Ç³£ÔçÆÚµÄÒÖÖÆÏ¸¾úµ°°×Öʵĺϳɡ£ÎÒÃÇ×¼±¸ÁËÁ½¸öÇ¿ÓÐÁ¦µÄ¡¢ºÏ³Éoxazolidinones,U-100592ºÍU-100766,ĿǰÕý´¦ÓÚÁÙ´²¿ª·¢ÓÃÓÚÖÎÁÆÑÏÖØµÄ̵Һ¸ïÀ¼ÊÏÑôÐÔ¾ú¾úÖêÒýÆðµÄ¸ÐȾÁ´Çò¾úºÍÆÏÌÑÇò¾ú,enterococci¡£ÔÚÌåÍâºÍÌåÄÚ(po,(ËÄ)»î¶¯,¶Ô¾ßÓдú±íÐԵľúÖêU-100592 U-100766ÏàËÆµÄÍò¹ÅÃ¹ËØ¡£U-100592ºÍU-100766Õ¹ÏÖÔÚÌåÍâʵÑéÖжԷνáºË¡£Ò»¸öÐÂӱʵÓõIJ»¶Ô³ÆºÏ³É(5S)-(acetamidomethyl·´Ó¦ÒÑ¿ª·¢ºÍÊܹ͵ĺϳÉU-100592ºÍU-100766¡£ÕâÉæ¼°µ½µÄ·´Ó¦Óë(R)-glycidyl N-lithioarylcarbamates¶¡Ëá¡¢µ¼ÖÂÓÅÐãµÄ²úÁ¿ºÍ¸ß ¡¡¡¡¶ÔÓ³Ìå´¿¶ÈµÄÖмä(R)- 5 -(ÏȽ«·´Ó¦¡£ |
4Â¥2009-12-19 13:43:42














»Ø¸´´ËÂ¥